Lamotrigine (LTG) is one of the new anti-epileptic drug, which is only approved for Lennox-Gastaut syndrome (LGS) in JAPAN.
We report the efficacy of LTG in 2 patients with LGS.
[Case1] 24-year-old man. The brain tumor and hydrocephalus was founded at 4-months of age, and tumor resection was done at 6-months of age. LGS developed at 3 years of age. Seizures were intractable against the many antiepileptic drugs. LTG was added to sodium valproate (VPA) and zonisamide (ZNS), because the seizures became worse at 22-years of age. Seizures were dramatically improved following LTG therapy. Cessation of ZNS was possible because the patient was seizure free for 2-years.
[Case2] 22-year-old man. LGS developed after acute encephalitis at 1 year of age. Seizures were intractable against the medication with VPA, clonazepam, phenitoin and ZNS, so LTG was added at 20 years of age. After LTG therapy, seizures were decreased remarkably, but about six months after LTG therapy, seizures have increased.
LGS is extremely intractable epilepsy and its causes are greatly various. We suggest that the different efficacy of LTG therapy for LGS may be influenced by the underlying disease causing LGS.
View full abstract